Objectives: Previously, we found that long intergenic non-coding RNA-p21 (lincRNAp21) inhibited the development of human prostate cancer. However, the underlying molecular mechanisms are poorly understood. Here, we attempted to investigate the downstream targets of lincRNA-p21 in prostate cancer.
| INTRODUCTION
Prostate cancer is one of the most common malignant tumours, accounting for the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males worldwide. 1 After response to chemotherapy or surgical castration, patients invariably progress to castration-resistant prostate cancer and the treatment is limited. 2, 3 Although numerous studies have been performed on prostate cancer therapies, the molecular events involved in prostate cancer progression are not well characterized.
Recently, lincRNA-p21 has been widely investigated in various diseases. It was first reported as a direct transcriptional target of p53, 4 and some studies showed that it could regulate gene expression, 5 mRNA translation and protein stability. 6 The former researchers have confirmed that lincRNA-p21 is associated with hepatocellular carcinoma, 7 skin cancer, 8 colorectal cancer 9 and chronic lymphocytic leukaemia. 10 In addition, our previous study also revealed that lincRNA-p21 suppressed the development of human prostate cancer. 11 However, the mechanisms whereby lincRNA-p21 inhibits the progression of prostate cancer remain elusive.
Hyperactive aerobic glycolysis is frequently observed in various cancers. Pyruvate kinase M2 (PKM2) is identified as an important
isoenzyme of aerobic glycolysis. 12 Unlike PKM1 found in normal differentiated tissues, it is preferentially expressed in proliferating cells, *These authors contribute equally to this work.
including cancer cells. 13 Previous studies have established that its expression is up-regulated during embryonic development and tumour progression. [14] [15] [16] Some reports reveal that PKM2 promotes tumorigenesis via phosphorylating MCL2 or histone H3. 17, 18 In addition, PKM2 is regulated by mTOR signalling in cervical cancer 19, 20 and alterations of PTEN/AKT/PI3K/mTOR signalling are also found in prostate cancer. 21, 22 Although PKM2 activation of glycolysis largely contributes to PTEN-/AKT-/mTOR-induced cancer development, its expression and function in prostate cancer and relationship with lincRNA-p21 are largely unclear.
In this study, we reported that lincRNA-p21 reduced PKM2 abundance in a PTEN-/AKT-/mTOR-dependent manner. Knockdown of lincRNA-p21 prominently stimulated Warburg effect, which could be rescued by PKM2 suppression or rapamycin treatment. Furthermore, PKM2 silencing blunted the proliferation and tumorigenesis of prostate cancer cells with lowly expressed lincRNA-p21. The tumorigenic capacity was also suppressed by rapamycin or 3-Brpa intervention.
Importantly, lincRNA-p21 level exhibited inverse correlation with PKM2 expression in prostate cancer specimens. PKM2 high expression predicted poor survival in prostate cancer patients. Therefore, PKM2 might be a potential therapeutic target in prostate cancer with silenced lincRNA-p21. 
| MATERIALS AND METHODS

| Materials
| shRNA
shRNA was designed to target lincRNA-p21 and PKM2 in prostate cancer cells. ShlincRNA-p21, shPKM2 and control shRNA (shCtrl) lentivirus particles were obtained from GenePharma. The target sequences are listed as follows: lincRNA-p21: GGAGGACACAGGAGAGGCA; PKM2: GCTGTGGCTCTAGACACTA.
Lentivirus expressing human lincRNA-p21 and PKM2 were generated by subcloning their cDNA to the pSLIK lentivirus expression system. 293T cells were used for retroviral packaging. DU145 and LNCap cells were cultured with virus-containing supernatant in the presence of 8 mg/mL polybrene. After 48 hours, puromycin (1.5 mg/mL) or hygromycin (150 mg/mL) was used to select infected cells. 
| Cell proliferation assay
| Colony formation analysis
LincRNA-p21-silenced DU145 or LNCaP cells were further transfected with shRNA against negative control or PKM2 and seeded in 10 cm plates and incubated at 37°C with 5% CO 2 for 10 days. Then the plates were fixed with methanol, stained with Crystal violet solution and the colony numbers were counted using Photoshop software. Jiao Tong University. Glucose or lactate content was measured respectively using an Olympus AU5400 (Japan) and a Dade Behring RXL MAX system (Deerfield, Illinois, USA). The glucose consumption and lactate production were calculated and normalized to cell numbers.
| Glucose
| Western blot
Cell lysates were extracted from indicated cells or tumour tissues using 
| Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from human prostate cancer or adjacent normal tissues or indicated human prostate cancer cells using TRIzol reagent (Invitrogen). One micro gram of total RNA was reverse transcribed using One
Step RT-PCR Kit (Takara, Japan) following the manufacturer's instructions. Quantitative real-time PCR was performed with SYBR Green qPCR Mix (Takara) on an ABI-7500
RT-PCR system (Applied Biosystems, Foster City, CA, USA). β-actin serves as internal control. All the primer sequences used in this study are listed as follows: PKM2-F, 5′-CCATCCTCTACCGGCCCGTTG-3′,
| Tumour xenograft experiments
Equal numbers of indicated prostate cancer cells were subcutaneously implanted into the immunodeficient nude mice (6-week old, male BALB/c). Each cohort contained 8 mice.
For tumour-free and survival analysis, a total of 3 × 10 
| Statistical analysis
All the statistical data were expressed as the mean ± SD at least 3 independent experiments. Two-tailed Student's t test and 1-way ANOVA analysis were used to conduct comparisons between 2 groups and multiple groups respectively. Difference was statistically significant when P < .05. *P < .05; **P < .01; ***P < .001; ****P < .0001.
| RESULTS
| PKM2 expression is inversely correlated with lincRNA-p21 level in prostate cancer patients and predicts survival
We previously showed that lincRNA-p21 was dramatically downregulated in prostate cancer, and it inhibited the proliferation and tumorigenesis of prostate cancer cells. As PKM2 is highly expressed in tumour cells and promotes tumour progression, we investigated whether lincRNA-p21 correlated with PKM2 in prostate cancer.
Thirty-six prostate cancer tissues and matched normal prostate tissues were collected and expression of lincRNA-p21 and PKM2 was examined by qRT-PCR and Western blot. We found that 67% ( lincRNA-p21 level and PKM2 expression ( Figure 1G ). Likewise, we detected the expression of PKM2 in the prostate cancer specimens and separate normal tissues which were used in our previous study.
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The results showed that PKM2 was significantly up-regulated in those prostate cancer tissues ( Figure 1H ). Taken together, these data indicate that lincRNA-p21 expression is inversely correlated with PKM2 expression in prostate cancer patients.
To explore whether highly expressed PKM2 was associated with prostate cancer progression, we next determined the relationship between PKM2 expression and patients' survival. We divided the patients into PKM2 high expression group (n = 39) and PKM2 low expression (n = 42) group. Our results showed that PKM2 high expression predicted poor survival of prostate cancer patients (Figure 2A,B) .
Likewise, this correlation was also observed in another separate cohort ( Figure 2C,D) . These results suggest that up-regulated PKM2 in prostate cancer may contribute to disease progression.
| Up-regulation of PKM2 induced by lincRNA-p21 silencing is dependent on PTEN/AKT/ mTOR cascade
To examine whether there is a regulatory relationship between lincRNA-p21 and PKM2, lincRNA-p21 was knocked down in DU145
and LNCaP cells. Reduction of lincRNA-p21 led to enhanced protein and mRNA levels of PKM2 ( Figure 3A-D) . PTEN/AKT/mTOR cascade is a key oncogenic signalling pathway in prostate cancer and has been reported to be a stimulator of PKM2. and LNCaP cells ( Figure 3G ). As expected, lincRNA-p21 overexpression in DU145 and LNCaP cells decreased PKM2 abundance ( Figure 3H,I ). In summary, lincRNA-p21 is a negative regulator of PKM2 and this regulatory mechanism is dependent on PTEN/AKT/ mTOR cascade. Figure 4C ). Our previous study showed that p53 was down-regulated after lincRNA-p21 knockdown.
Because p53 silencing promotes aerobic glycolysis, 23 we overexpressed P53 in lincRNA-p21-silenced DU145 cells and found that PKM2 level, glucose consumption and lactate production remained no change after P53 overexpression ( Figure S1 ). As reactive oxygen species (ROS) plays an important role in cancer development, we also checked the ROS production and found that it did not change after lincRNA-p21 knockdown ( Figure S2 ). Therefore, our findings suggest that PKM2 up-regulation is critical for aerobic glycolysis activation in human prostate cancer cells with silenced lincRNA-p21.
| Knockdown of PKM2 suppresses the proliferation of prostate cancer cells with reduced lincRNA-p21 expression
To identify the effects of PKM2 on prostate cancer cell proliferation, shRNA against PKM2 was stably transfected in DU145 and LNCaP cells harbouring silenced lincRNA-p21. CCK8 results showed that the viability of DU145 cells was dramatically suppressed after PKM2 knockdown ( Figure 5A ). Consistently, the colony-forming capacity of DU145 cells was also inhibited (Figure 5B,C) . Likewise, similar results were observed in LNCaP cells ( Figure 5D-F) . It is well known that rapamycin and 3-Brpa are promising drugs specifically against mTOR and glycolysis respectively. Next, we treated shlincRNA-p21 and shCtrl DU145 cells with rapamycin or 3-Brpa at various concentrations.
We found that lincRNA-p21-knockdown DU145 cells were more sensitive to rapamycin and 3-Brpa treatment ( Figure 5G,H) . These results strongly suggest that PKM2 or glycolysis inhibition significantly blunts the proliferation of lincRNA-p21-silenced prostate cancer cells.
| Knockdown of PKM2 inhibits the nude mice tumorigenicity of lincRNA-p21-silenced prostate cancer cells
As PKM2 deficiency has been shown to inhibit the proliferation of prostate cancer cell, we next tested whether PKM2 knockdown could suppress tumour growth in vivo. LincRNA-p21-silenced DU145 and LNCaP cells expressing shPKM2 or shCtrl were injected into nude mice to establish a xenographic tumour model and tumour growth was assessed.
Percentage of tumour-free and survival was analysed 3 weeks after LNCaP cell implanted into nude mice (details in Materials and Methods).
Our results showed that inhibition of PKM2 prominently attenuated tumour initiation and progression of LNCaP cells in nude mice ( Figure 6A ).
Likewise, targeting PKM2 blunted the tumorigenic capacity of lincRNAp21 DU145 cells in nude mice ( Figure 6B ). Thus, our results showed that PKM2 suppression dramatically inhibited tumour growth and progression in vivo.
| 3-Brpa or rapamycin reduces the tumour progression of prostate cancer cells in the nude mice
It has been shown that rapamycin or 3-Brpa suppressed the proliferation LNCaP cells remained unchanged after androgen treatment ( Figure S3B ).
In conclusion, rapamycin or glycolytic inhibitor might be a promising therapeutic strategy for prostate cancer patients with lowly expressed lincRNA-p21.
| DISCUSSION
Increasing evidences show that lincRNA-p21 plays a vital role in various cancer types, including lung cancer, 25 head and neck cancer, 26 and liver cancer. 7 LincRNA-p21 is identified as a tumour suppressive long non-coding RNA (lncRNA) in hepatocellular carcinoma. 7 Besides, our previous study showed that lincRNA-p21 inhibited the development PI3K/AKT/mTOR signalling pathway plays a crucial role in cancer development, including prostate cancer. 21 This pathway is a key regulator of cellular metabolism, involved in glucose uptake, glycolysis, fatty acid oxidation and protein synthesis. 27 In response to insulin, the activity of PI3K/AKT signalling is enhanced, resulting in hyperactivation of mTOR. 27, 28 Hyper-activation of mTOR signalling leads to increased mRNA transcription and protein synthesis, 29, 30 thus promoting cell proliferation and growth. In addition, activation of this pathway also results in enhanced PKM2 abundance. However, the potential relationship between lincRNA-p21 and the signalling pathway is less explored. In our study, we found that PKM2 was up-regulated and AKT or mTOR signalling was activated after lincRNA-p21 knockdown.
Moreover, up-regulated PKM2 was inhibited by AKT or mTOR inhibitor treatment, suggesting that increased PKM2 expression induced by lincRNA-p21 reduction depends on PTEN/AKT/mTOR cascade. Also, decreased PTEN level indicated that PTEN might be a direct target of lincRNA-p21, while the precise regulatory relationship remains to be determined.
It is well known that aerobic glycolysis is a hallmark of cancer, and that increased glucose consumption and elevated lactate production are key characteristics of cancer cell. 31 Recently, it was thought that aerobic glycolysis favours various biosynthetic pathways and then provides the metabolic requirements for proliferation. Initially, we observed that the culture medium of lincRNA- 23 and our previous study found that p53 was down-regulated after lincRNA-p21
knockdown. Thus, we overexpressed p53 in shlincRNA-p21 DU145 cells and detected the glycolysis. However, the expression of PKM2, glucose consumption and lactate production remained unchanged, suggesting that lincRNA-p21 negatively regulated aerobic glycolysis independent of p53 signalling. As androgen is a key regulator of prostate cancer development and aerobic glycolysis, we also analysed whether lincRNA-p21 down-regulation of PKM2, aerobic glycolysis was dependent of androgen. We first treated LNCaP cells with androgen and found that androgen did not affect the expression of lincRNA-p21. In addition, enhanced PKM2 expression and glycolysis in shlincRNA-p21 LNCaP cells remained unchanged after androgen treatment, revealing that the regulation is independent of androgen.
Pyruvate kinase M2 plays a vital role in regulating anabolic metabolism including aerobic glycolysis. Previous studies revealed that PKM2 was commonly up-regulated in human cancer cells. [14] [15] [16] Therefore, targeting PKM2 or aerobic glycolysis is recognized as a promising therapeutic strategy in various human cancer. However, the outcomes are still less satisfactory, mainly due to frequent relapse and severe side effects. Our in vitro results showed that 
